Akero Therapeutics Inc’s recently made public that its Chief Scientific Officer Rolph Timothy unloaded Company’s shares for reported $0.56 million on Mar 05 ’25. In the deal valued at $44.53 per share,12,500 shares were sold. As a result of this transaction, Rolph Timothy now holds 170,237 shares worth roughly $7.1 million.
Then, Young Jonathan sold 50,000 shares, generating $2,243,213 in total proceeds. Upon selling the shares at $44.86, the Chief Operating Officer now owns 201,147 shares.
Before that, Lamy Patrick sold 1,000 shares. Akero Therapeutics Inc shares valued at $48,090 were divested by the Senior VP, Commercial Strategy at a price of $48.09 per share. As a result of the transaction, Lamy Patrick now holds 33,492 shares, worth roughly $1.4 million.
BofA Securities upgraded its Akero Therapeutics Inc [AKRO] rating to a Buy from a a Neutral in a research note published on January 30, 2025; the price target was increased to $63 from $35. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late January has reiterated a ‘”a Buy”‘ rating for it. Citigroup began covering AKRO with “Buy” recommendation on November 18, 2024.
Price Performance Review of AKRO
On Monday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock fall -1.04% to $41.68. Over the last five days, the stock has lost -8.48%. Akero Therapeutics Inc shares have risen nearly 49.82% since the year began. Nevertheless, the stocks have risen 38.93% over the past one year. While a 52-week high of $58.40 was reached on 01/27/25, a 52-week low of $17.86 was recorded on 01/14/25. SMA at 50 days reached $40.45, while 200 days put it at $30.36.
Levels Of Support And Resistance For AKRO Stock
The 24-hour chart illustrates a support level at 41.04, which if violated will result in even more drops to 40.39. On the upside, there is a resistance level at 42.44. A further resistance level may holdings at 43.19. The Relative Strength Index (RSI) on the 14-day chart is 39.57, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -4.46, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.43%. Stochastics %K at 2.35% indicates the stock is a buying.
The most recent change occurred on September 19, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $69 price target.
